Expansion through Licensing GSK's recent licensing agreement with Alfasigma, which grants exclusive development and marketing rights for Lynavoy worldwide, presents opportunities to collaborate on commercializing this innovative therapy and expanding market reach in liver disease treatments.

Diverse Product Portfolio With a broad range of household consumer healthcare brands like Sensodyne and Panadol, GSK offers multiple channels for sales expansion, including household retail and over-the-counter segments, enabling tailored marketing strategies for diverse consumer needs.

Innovative R&D Focus GSK’s ongoing development of treatments like linerixibat and strategic acquisitions of biotech assets signal a strong pipeline focused on high unmet medical needs, presenting opportunities for partnerships in early-stage therapies and novel drug development.

Strategic Acquisitions The planned $950 million acquisition of 35Pharma Inc. and recent asset deals, including a $1 billion biotech license deal, demonstrate GSK’s proactive approach in expanding its biotech portfolio, creating potential for joint ventures and licensing opportunities in cutting-edge therapies.

Global Healthcare Commitment As a research-driven global healthcare company actively addressing diseases prioritized by WHO such as HIV/AIDS, tuberculosis, and malaria, GSK offers avenues for collaboration in infectious disease solutions and vaccines tailored to regional health needs, opening opportunities in public health-focused sales.